Every 10-Q that Heartcore Enterprises, Inc. (HTCR) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow HTCR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full HTCR filings page.
HeartCore Enterprises, Inc. reported weak results for the quarter and six months ended June 30, 2026 while disclosing substantial doubt about its ability to continue as a going concern. For the quarter, revenues from continuing operations were $321,428, up from $187,277 a year earlier, but higher costs drove a gross loss of $70,215 and a loss from continuing operations of $1,550,289. Including discontinued operations, the quarterly net loss attributable to the company was $2,023,080, or $(1.45) per basic share.
For the first half of 2026, revenues were $553,926 and the net loss attributable to the company reached $3,894,787, with net cash used in operating activities of $2,482,756. Cash and cash equivalents fell to $587,074, and working capital was about $0.6 million against an accumulated deficit of $17.7 million. The company completed the sale of its Sigmaways business, continued accounting for HeartCore Japan and Sigmaways as discontinued operations, and relied significantly on marketable securities of $2,668,317 for liquidity. Management is exploring equity, debt and operational restructuring alternatives but states it cannot conclude these plans are probable of success, and no going-concern adjustments have been recorded.
HeartCore Enterprises, Inc. reported a weak first quarter of 2026 as it continues its shift toward U.S. IPO consulting services. Revenue from continuing operations was $1.25 million for the three months ended March 31, 2026, down from $2.09 million a year earlier, mainly reflecting lower customized software and consulting revenue. Gross profit fell sharply to $74,045, and the company posted a net loss from continuing operations of $1.98 million, though this was narrower than the prior-year loss.
Liquidity remains strained. Cash and cash equivalents were just $774,033 as of March 31, 2026, with working capital of about $1.0 million and an accumulated deficit of $15.6 million. Operating activities used $1.15 million of cash in the quarter, and management explicitly states that these conditions raise “substantial doubt” about the company’s ability to continue as a going concern.
The business is now focused on its “Go IPO” consulting model, with 16 active client agreements that combine cash fees of $380,000 to $900,000 per client and equity-linked consideration via warrants or stock acquisition rights. HeartCore also holds $3.39 million in marketable securities and $273,859 in warrants received from clients, but faces ongoing losses, interest-bearing debt, a derivative liability tied to Series A convertible preferred shares, and execution risk in raising additional capital despite an equity line, an at-the-market program, and a newly authorized $2.0 million share repurchase program.
HeartCore Enterprises (HTCR) reported a small Q3 2025 profit but weaker year-to-date results as it prepares for a major business shift. For the quarter ended September 30, 2025, total revenue from continuing operations was $2,990,329, compared with $16,240,865 a year earlier, reflecting much lower consulting revenue. Gross profit was $1,468,409 and income from continuing operations was a modest loss of $137,122, while discontinued operations contributed income of $488,297, leading to net income of $351,175 and $377,850 attributable to common shareholders.
For the nine months ended September 30, 2025, revenue from continuing operations was $7,052,799 versus $21,270,891 in the prior-year period, and the company posted a net loss of $1,724,700 compared with net income of $7,127,810. Cash and cash equivalents were $1,451,019 and total assets $13,337,171, with shareholders’ equity of $3,824,618. During 2025, HeartCore issued 2,000 Series A convertible preferred shares with an aggregate liquidation preference of $2,256,833 and recorded a $245,820 derivative liability.
A key strategic change is the sale of HeartCore Japan. The board approved a plan on July 24, 2025 to sell 100% of HeartCore Japan, which was treated as a discontinued operation, and the transaction closed on October 31, 2025. This divestiture removes a major historical contributor from future results and leaves the company focused on software development and public-listing consulting through its remaining subsidiaries.
HeartCore Enterprises, Inc. (HTCR) reported a strong quarterly turnaround for the three months ended June 30, 2025, with revenue of $4.74 million (up from $4.07 million a year earlier) and net income of $1.06 million, reversing a prior-year quarter loss. Gross profit widened to $2.22 million, aided by a $852,709 fair value gain on marketable securities and other investment revaluations.
For the six months ended June 30, 2025, revenue totaled $8.33 million (down from $9.11 million), producing a six-month net loss of $2.08 million. Operating cash flows used $2.67 million in the period. The company closed a securities purchase that generated $1.8 million net proceeds and issued a 2,000-share Series A convertible preferred designation, while also entering an equity purchase facility for up to $25 million. Key balance-sheet items include cash of $2.35 million, accounts receivable of $4.06 million and a $500,000 customer refund liability due August 2025.